Neurimmune Therapeutics AG Awarded the 2010 ZKB TECHNOPARK Pioneer Award
The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which are about to be launched on the market. This year’s award winner is Neurimmune Therapeutics AG, represented by Dr. Jan Grimm, Professor Christoph Hock, Professor Roger Nitsch and Dr. Michael Salzmann. The award honors their internationally unique research work in the development of drugs for the prevention and treatment of Alzheimer’s disease.
Neurimmune Therapeutics AG received the award for its avenue of research known as RTM™ (Reverse Translational Medicine) for the treatment and cure of Alzheimer’s disease. Neurimmune’s technology platform identifies immunologic factors that help keep elderly people cognitively healthy. It employs sophisticated technology to identify health-maintaining antibodies and produces them biotechnologically. It has already been demonstrated in animals that it is possible not only to halt the death of nerve cells in the brain characteristic of Alzheimer’s disease, but also to actually restore their function. Clinical trials are anticipated to begin next year.
Alzheimer’s disease is the most prevalent age-related neurodegenerative disease affecting more than 35 million patients worldwide. There are currently no treatments approved to slow or stop the progression of the disease. Patients with Alzheimer’s disease experience the progressive loss of cognitive functions, particularly those related to memory, followed by death after a progressive decline in their disease. The pathology of Alzheimer’s disease is characterized by the deposition of beta-amyloid in senile plaques, the formation of neurofibrillary tangles, and the loss of specific neuronal populations in the brain.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
